Navigation Links
Shamir Optical Industry Ltd. to Host Conference Call Announcing Fourth Quarter and Year End 2007 Earnings Results
Date:2/27/2008

KIBBUTZ SHAMIR, Israel, Feb. 27 /PRNewswire-FirstCall/ -- Shamir Optical Industry Ltd. (Nasdaq: SHMR) ("Shamir") expects to issue its fourth quarter and year end 2007 earnings results on Thursday, March 6, 2008, and has scheduled a conference call to discuss the results at 9:00 A.M. EST that morning.

The conference call will be broadcast live as a listen-only webcast. To listen live, please go to http://www.kcsa.com approximately five minutes before the conference call is scheduled to begin. You will need to register, and may need to download and install the required audio software. The webcast will be archived for 30 days following the call.

About Shamir

Shamir is a leading provider of innovative products and technology to the progressive spectacle lens market. Utilizing its proprietary technology, the company develops, designs, manufactures, and markets progressive lenses to sell to the ophthalmic market. In addition, Shamir utilizes its technology to provide design services to optical lens manufacturers under service and royalty agreements. Progressive lenses are used to treat presbyopia, a vision condition where the eye loses its ability to focus on close objects. Progressive lenses combine several optical strengths into a single lens to provide a gradual and seamless transition from near to intermediate, to distant vision. Shamir differentiates its products from its competitors' primarily through lens design. Shamir's leading lenses are marketed under a variety of trade names, including Shamir Genesis(TM), Shamir Piccolo(TM), Shamir Office(TM), and Shamir Autograph(TM). Shamir believes that it has one of the world's preeminent research and development teams for prog
'/>"/>

SOURCE Shamir Optical Industry Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Shamir Optical Industry Ltd. to Host Conference Call Announcing Third Quarter 2007 Earnings Results
2. Optical scientist honored for understanding and improving vision
3. Minority patients prefer optical colonoscopy for colorectal cancer screening
4. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
5. Optical Coherence Tomography Market to Top $800 Million by 2012
6. Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site
7. Optical frequency comb can detect the breath of disease
8. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
11. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... Holdings has announced that it has become a natio...e largest nonprofit organizations dedicated to art... Delray Beach, FL (Vocus) Nov...XCHO), a company specializing in the marketing and...ts, has announced today that is has become a natio...
(Date:11/27/2009)...ealth™ announced today that Spectrum Health ...d Enterprise orthopedic templating solution and it... (PRWEB) November 27, 2009 -- Voyant...h (Grand Rapids, Michigan) has licensed its Trauma...its TraumaCad Extend workflow solution, to allow i...
(Date:11/26/2009)...--Withcoldandfluseasonuponus,it,smoreimportantthan...tionsandavoidillness. ,, "Weneedtobeproactiveno...illnessifwe,resick,"saidEileenFinerty,RN,MS,CIC(ce...ctioncontrolandoccupationalhealthatHospitalforSpec...alSurgeryhasoneofthelowestinfectionratesofanyhospi...
(Date:11/26/2009)...y can lead to strains or worse , , THURS...ing wrong with stuffing your turkey full to bursti...th your suitcase as you pack for holiday trips. ,... U.S. hospital emergency rooms, doctors, offices, ...elated injuries, such as muscle strains, pulls and...
(Date:11/26/2009)... Triangle Dental (RTDental), a leading dental grou...ced the expansion of its services to include LUMIN...millan. , Durham, NC (...nnounce that Dr. Doug Macmillan, an experienced L...l advanced training seminar. RTDental’s abi...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
...Food and Drug Administration (FDA) today announced...and Factor Complex (Human), Alphanate. //The produ...invasive procedures with von Willebrand disease (v...oing major surgery. The disease is the most common...
...m (Tamil Nadu): Over 3,000 transsexuals in Tamil N...hat society will now "see" them differently.// ...n AIDS awareness campaigner from Vellore and pledg...ervices. The mass eye donation by the 'arav...
...s have found more than 250 species of bacteria dw...animal //species in a zoo, which prompts lead rese...acteria out there on the human body. Stating t...er says he was astounded by results of his work, w...
..., a drug used for limiting blood loss in patients ...increased risk of death during five years followin...rotinin was first approved for use in high-risk pa...ion patients worldwide have received aprotinin sin...
...y published in Clinical Pediatrics, it is reported...itamin D. If this deficit is taken care of, their ...ency disorders. Joyce M. Lee and his team belo...nd to be deficient in vitamin D. Among their child...
...rs have found that wisdom in old age depends on a ...researchers found that when mature mice learn a ne...e times more active than their old ones, the New S...roup of mice with a chemical agent that stains onl...
Other Medicine News:Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:The Other Side of Transsexuals 2Health News:Unknown Species of Bacteria Among a ‘zoo’ of Them on the Human Bo 2Health News:Drug Used in Coronary Artery Bypass Surgery may Increase Risk of Death 2
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...ry-USMarketTrends&Analysis http://www.reportl...arket-Trends--Analysis.html ,, TheUSintranasal...uticapplicationsfromthedeliveryofconventionallocal...drugs.Thefutureofthetechnologyhingesontotheeffecti...
(Date:11/25/2009)...re/-- ChemoCentryx,Inc.,announcedtodaythatPhaseII...ectiveRandomizedOralTherapyEvaluationinCrohn,sdise...moderate-to-severeCrohn,sdiseasedemonstratedclinic...le.Thestudydemonstratedevidenceofclinicalefficacyi...decreaseintheCrohn,sDiseaseActivityIndex(CDAI)inpa...
(Date:11/24/2009)...stCall/--Endologix,Inc.(Nasdaq: ELGX ),developerof...uncedtodaythatithasfiledamotiontostay,ordiscontinu...ghtagainstitinOctober2009byCook,Inc.Themotionwasfi...diana. ,, Endologixhasrequestedthatthestayremai...ice(USPTO)conductsproceedingstore-examinethetwopat...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 1National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 2National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 3National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 4National Expressions of Courage Art Contest Unveils Stories of Inspiration 6277 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 1Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 2Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 3Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 4Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 5Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 6Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 7Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 8Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 9Lotus Pharmaceuticals Inc Reports Third Quarter 2009 Results 6274 10
...linical program to evaluate PROMUS(TM) Element(TM)...3 Boston Scientific Corporation (NYSE: BSX ) to...in the PLATINUM clinical trial, which is designed ...verolimus-Eluting Coronary Stent. The first U.S. ...er of the Rockies in Loveland, Colorado by Thomas ...
...NG-WEIHENSTEPHAN, Germany, February 3 Pieris AG, ...R), a novel class of targeted,human protein therap...,progress in the development of its Anticalin(R) c...oad therapeutic applicability. , Having succes...in vitro,and in vivo, Pieris has now validated the...
Other Medicine Technology:Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 2Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 3Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 4Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent 5Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 2Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist 3
IMMULITE/IMMULITE 1000 Cortisol
...ors from KUBTEC represents a stand-alone, high-res...to 16 bit digital interface. The large sensing are... spacing down to 48 microns. All models are availa...ed energy range (10-160 kV). Applications range fr...
...UBTEC is a dual capability system with the ability...on of the specimen under test. While the XCAT seri...X-ray images, the micro focus source also allows t...ard 2D images. The 100 mm x 100 mm digital detecto...
...men radiography. The XPERT represents a research t...n every digital x-ray image, thus being able to ca...ore were lost to the human eye. With features incl...e, multi-color digital operator interface, and a 1...
Medicine Products: